Charles River Laboratories International, Inc. (CRL)
NYSE: CRL · Real-Time Price · USD
345.37
+5.71 (1.68%)
At close: Oct 23, 2026, 4:00 PM EDT
345.00
-0.37 (-0.11%)
After-hours: Oct 23, 2026, 7:57 PM EDT
CRL Revenue
Charles River Laboratories International had revenue of $1.00B in the quarter ending June 27, 2026, a decrease of -2.72%. This brings the company's total for the last twelve months to $4.00B, down -0.74% year-over-year. In the year 2025, Charles River Laboratories International had annual revenue of $4.02B, down -0.85%. That makes Charles River Laboratories International the 3,076th largest company in the world by revenue and 872nd in the United States.
Revenue (ttm)
$4.00B
Revenue Growth
-0.74%
P/S Ratio
4.12
Revenue / Employee
$202,994
Employees
19,700
Market Cap
16.49B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full CRL breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 27, 2025 | 4.02B | -34.61M | -0.85% |
| Dec 28, 2024 | 4.05B | -79.42M | -1.92% |
| Dec 30, 2023 | 4.13B | 153.35M | 3.86% |
| Dec 31, 2022 | 3.98B | 435.90M | 12.31% |
| Dec 25, 2021 | 3.54B | 616.23M | 21.08% |
| Dec 26, 2020 | 2.92B | 302.71M | 11.55% |
| Dec 28, 2019 | 2.62B | 355.13M | 15.67% |
| Dec 29, 2018 | 2.27B | 408.50M | 21.99% |
| Dec 30, 2017 | 1.86B | 176.17M | 10.48% |
| Dec 31, 2016 | 1.68B | 318.13M | 23.34% |
| Dec 26, 2015 | 1.36B | 65.64M | 5.06% |
| Dec 27, 2014 | 1.30B | 132.13M | 11.34% |
| Dec 28, 2013 | 1.17B | 36.00M | 3.19% |
| Dec 29, 2012 | 1.13B | -13.12M | -1.15% |
| Dec 31, 2011 | 1.14B | 9.23M | 0.81% |
| Dec 25, 2010 | 1.13B | -38.23M | -3.26% |
| Dec 26, 2009 | 1.17B | -123.66M | -9.55% |
| Dec 27, 2008 | 1.30B | 64.67M | 5.26% |
| Dec 29, 2007 | 1.23B | 172.24M | 16.27% |
| Dec 30, 2006 | 1.06B | 65.06M | 6.55% |
| Dec 31, 2005 | 993.33M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Labcorp Holdings | 14.35B |
| Quest Diagnostics | 11.84B |
| ICON Public Limited Company | 8.29B |
| Waters | 4.64B |
| IDEXX Laboratories | 4.55B |
| Illumina | 4.49B |
| Mettler-Toledo International | 4.13B |
| Revvity | 2.91B |
CRL News
- 2 days ago - Charles River, Labcorp, FDA to partner on study of drug abuse potential - TheFly
- 2 days ago - Labcorp, Charles River and FDA to collaborate to evaluate drug abuse potential - TheFly
- 2 days ago - Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment - Business Wire
- 11 days ago - Charles River announces collaboration with Magellan Stem Cells - TheFly
- 11 days ago - Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development - Business Wire
- 12 days ago - Charles River price target raised to $340 from $300 at Morgan Stanley - TheFly
- 15 days ago - Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call - Business Wire
- 18 days ago - Charles River, Autolomous announce launch of Apollo Orchestrate - TheFly